Last reviewed · How we verify

NCT04192773

An fMRI Investigation of the Effects of IV Lidocaine on Tinnitus

Recruiting now EARLY_PHASE1 Last updated 2 December 2025
What this trial tests

EARLY_PHASE1 trial testing IV Lidocaine in Tinnitus in 40 participants. Currently enrolling.

Timeline
28 April 2021
Primary endpoint
31 December 2027
31 December 2027

Quick facts

Lead sponsorD. Bradley Welling, MD, PhD
PhaseEARLY_PHASE1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment40
Start date28 April 2021
Primary completion31 December 2027
Estimated completion31 December 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

D. Bradley Welling, MD, PhD — full company profile →

Who can join

18 and older, any sex, with Tinnitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an exploratory pilot open-label study to identify the signal changes on fMRI of patients with tinnitus and with temporary suppression of the tinnitus with IV lidocaine. Patients will include those with hearing loss (both unilateral and bilateral) and tinnitus, subjects with normal hearing and tinnitus, and control subjects with normal hearing and no tinnitus. Eligible subjects will have functional and subjective data collected at baseline, receive an IV lidocaine infusion, and have functional and subjective data collected post-infusion for comparison and identification of involved neural networks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of IV Lidocaine

Trials testing the same drug.

Other recruiting trials for Tinnitus

Currently open trials in the same condition.

Other D. Bradley Welling, MD, PhD trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04192773.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing